Antibody molecules having binding specificity for human il-13
AssigneeUCB Pharma S.A.
InventorsNEIL GOZZARD, ALASTAIR DAVID GRIFFITHS LAWSON, DANIEL JOHN LIGHTWOOD, ROGER THOMAS PALFRAMAN, BRYAN JOHN SMITH, KERRY LOUISE TYSON
Life of this patent
Estimating the term…
Abstract
The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
Claims28
An antagonistic antibody which binds human IL-13 comprising a heavy chain, wherein the variable domain of the heavy chain comprises at least one of a CDR having the sequence given in SEQ ID NO:1 for CDR-H1, a CDR having the sequence given in SEQ ID NO:2 for CDR-H2 and a CDR having the sequence given in SEQ ID NO:3 for CDR-H3.
An antagonistic antibody which binds human IL-13, comprising a light chain, wherein the variable domain of the light chain comprises at least one of a CDR having the sequence given in SEQ ID NO:4 for CDR-L1, a CDR having the sequence given in SEQ ID NO:5 for CDR-L2 and a CDR having the sequence given in SEQ ID NO:6 for CDR-L3.
An antagonistic antibody which binds human IL-13, wherein the variable domain of the heavy chain comprises three CDRs and the sequence of CDRH-1 has at least 60% identity or similarity to the sequence given in SEQ ID NO:1, the sequence of CDRH-2 has at least 60% identity or similarity to the sequence given in SEQ ID NO:2 and the sequence of CDRH-3 has at least 60% identity or similarity to the sequence given in SEQ ID NO:3.
An antagonistic antibody which binds human IL-13, having a heavy chain comprising the sequence given in SEQ ID NO:31 and a light chain comprising the sequence given in SEQ ID NO:23.
An antagonistic antibody which binds human IL-13, having a heavy chain comprising the sequence given in SEQ ID NO:35 and a light chain comprising the sequence given in SEQ ID NO:27.
An antagonistic antibody having a binding affinity for isolated human IL-13 of 30 pM or better.
A method for the treatment of a human subject suffering from or at risk of a pathological disorder mediated by IL-13, the method comprising administering to the subject an effective amount of an anti-IL-13 antibody Fab or Fab′ fragment by inhalation.
The method according to any one of claims 24 to 28 wherein the pathological disorder is selected from the group consisting of:
- asthmatic disorders, atopic disorders, chronic obstructive pulmonary disease (COPD), conditions involving airway inflammation, eosinophilia, fibrosis and excess mucus production, inflammatory conditions, autoimmune conditions, tumors or cancers, viral infection and suppression of expression of protective type 1 immune responses.
Dependencies are inferred from the claim text.